As of 2024-12-12, the Relative Valuation of Arbutus Biopharma Corp (ABUS) is (9.33) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.64 USD, the upside of Arbutus Biopharma Corp based on Relative Valuation is -356.3%.
The range of the Relative Valuation is (8.73) - (8.15) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.6x - 31.4x | 26.5x |
| Forward P/E multiples | 19.1x - 20.1x | 19.6x |
| Fair Price | (8.73) - (8.15) | (9.33) |
| Upside | -340.0% - -324.0% | -356.3% |
| Date | P/E |
| 2024-12-06 | -9.09 |
| 2024-12-05 | -8.97 |
| 2024-12-04 | -9.24 |
| 2024-12-03 | -8.42 |
| 2024-12-02 | -8.55 |
| 2024-11-29 | -8.55 |
| 2024-11-27 | -8.57 |
| 2024-11-26 | -8.42 |
| 2024-11-25 | -8.45 |
| 2024-11-22 | -8.67 |
| 2024-11-21 | -8.55 |
| 2024-11-20 | -8.50 |
| 2024-11-19 | -8.62 |
| 2024-11-18 | -8.70 |
| 2024-11-15 | -8.99 |
| 2024-11-14 | -8.97 |
| 2024-11-13 | -9.02 |
| 2024-11-12 | -8.99 |
| 2024-11-11 | -9.22 |
| 2024-11-08 | -9.26 |
| 2024-11-07 | -9.22 |
| 2024-11-06 | -9.68 |
| 2024-11-05 | -9.78 |
| 2024-11-04 | -9.56 |
| 2024-11-01 | -9.78 |
| 2024-10-31 | -9.50 |
| 2024-10-30 | -9.73 |
| 2024-10-29 | -9.98 |
| 2024-10-28 | -10.01 |
| 2024-10-25 | -9.81 |
| 2024-10-24 | -10.01 |
| 2024-10-23 | -10.03 |
| 2024-10-22 | -9.96 |
| 2024-10-21 | -10.06 |
| 2024-10-18 | -10.25 |
| 2024-10-17 | -10.18 |
| 2024-10-16 | -10.38 |
| 2024-10-15 | -10.15 |
| 2024-10-14 | -9.54 |
| 2024-10-11 | -9.59 |
| 2024-10-10 | -9.36 |
| 2024-10-09 | -9.29 |
| 2024-10-08 | -9.31 |
| 2024-10-07 | -9.22 |
| 2024-10-04 | -9.49 |
| 2024-10-03 | -9.51 |
| 2024-10-02 | -9.64 |
| 2024-10-01 | -9.46 |
| 2024-09-30 | -9.51 |
| 2024-09-27 | -9.46 |